TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maternal Micronutrient Supplementation to Reduce Low Birth Weight and Infant and Maternal Morbidity in Rural Nepal
Brief Summary: The purpose of this study was to determine the effects of providing supplements containing alternative combinations of micronutrients during pregnancy on birth weight and other infant and maternal health and nutritional outcomes in a rural area of Nepal.


Options:
A: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A
B: Arm Label: Dietary Supplement/Vitamins; Type: EXPERIMENTAL; Interventions: Drug: Dietary Supplement/Vitamins | Arm Label: Placebo for Vitamin C and Vitamin E; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Vitamin C and Vitamin E | Intervention Type: DRUG; Name: Dietary Supplement/Vitamins; Assigned to Arm(s): Dietary Supplement/Vitamins | Intervention Type: DRUG; Name: Placebo for Vitamin C and Vitamin E; Assigned to Arm(s): Placebo for Vitamin C and Vitamin E
C: Arm Label: MMN; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple micronutrient supplements (MMN) | Arm Label: IFA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: IFA | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple micronutrient supplements (MMN); Assigned to Arm(s): MMN | Intervention Type: DIETARY_SUPPLEMENT; Name: IFA; Assigned to Arm(s): IFA
D: Arm Label: 400 micrograms of folic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Folic acid: 4 mg versus 0.4 mg per day | Arm Label: 4mg of folic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Folic acid: 4 mg versus 0.4 mg per day | Intervention Type: DRUG; Name: Folic acid: 4 mg versus 0.4 mg per day; Assigned to Arm(s): 400 micrograms of folic acid, 4mg of folic acid

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maternal Micronutrient Supplementation to Reduce Low Birth Weight and Infant and Maternal Morbidity in Rural Nepal
Brief Summary: The purpose of this study was to determine the effects of providing supplements containing alternative combinations of micronutrients during pregnancy on birth weight and other infant and maternal health and nutritional outcomes in a rural area of Nepal.


Options:
A: Arm Label: MMN; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple micronutrient supplements (MMN) | Arm Label: IFA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: IFA | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple micronutrient supplements (MMN); Assigned to Arm(s): MMN | Intervention Type: DIETARY_SUPPLEMENT; Name: IFA; Assigned to Arm(s): IFA
B: Arm Label: Multivitamins-Single RDA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamins-Single RDA | Arm Label: Multivitamins-Multiples of RDA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins-Multiples of RDA | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins-Multiples of RDA; Assigned to Arm(s): Multivitamins-Multiples of RDA | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins-Single RDA; Assigned to Arm(s): Multivitamins-Single RDA
C: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maternal Micronutrient Supplementation to Reduce Low Birth Weight and Infant and Maternal Morbidity in Rural Nepal
Brief Summary: The purpose of this study was to determine the effects of providing supplements containing alternative combinations of micronutrients during pregnancy on birth weight and other infant and maternal health and nutritional outcomes in a rural area of Nepal.


Options:
A: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A
B: N/A
C: Intervention Type: DIETARY_SUPPLEMENT; Name: Daminaide 995 - SuppleFem Sprinkles; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Materna; Assigned to Arm(s): N/A
D: Arm Label: Early umbilical cord clamping (control); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Delayed umbilical cord clamping; Type: EXPERIMENTAL; Interventions: Procedure: Delayed umbilical cord clamping | Intervention Type: PROCEDURE; Name: Delayed umbilical cord clamping; Assigned to Arm(s): Delayed umbilical cord clamping

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maternal Micronutrient Supplementation to Reduce Low Birth Weight and Infant and Maternal Morbidity in Rural Nepal
Brief Summary: The purpose of this study was to determine the effects of providing supplements containing alternative combinations of micronutrients during pregnancy on birth weight and other infant and maternal health and nutritional outcomes in a rural area of Nepal.


Options:
A: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Folate; Assigned to Arm(s): N/A
C: Arm Label: Folic acid; Type: OTHER; Interventions: Dietary Supplement: Folic acid | Arm Label: Placebo; Type: OTHER; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Folic acid | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ferrous fumarate (iron), Dietary Supplement: folic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Ferrous fumarate (iron); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maternal Micronutrient Supplementation to Reduce Low Birth Weight and Infant and Maternal Morbidity in Rural Nepal
Brief Summary: The purpose of this study was to determine the effects of providing supplements containing alternative combinations of micronutrients during pregnancy on birth weight and other infant and maternal health and nutritional outcomes in a rural area of Nepal.


Options:
A: Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Drug: Multivitamins | Arm Label: Multivitamins + Zinc; Type: EXPERIMENTAL; Interventions: Drug: Zinc, Drug: Multivitamins | Arm Label: Zinc; Type: EXPERIMENTAL; Interventions: Drug: Zinc | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): Multivitamins + Zinc, Zinc | Intervention Type: DRUG; Name: Multivitamins; Assigned to Arm(s): Multivitamins, Multivitamins + Zinc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Fe, Zn, Fe+Zn, Placebo; Type: N/A; Interventions: N/A
C: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: zinc | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: iron + copper | Intervention Type: DIETARY_SUPPLEMENT; Name: zinc; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: iron + copper; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maternal Micronutrient Supplementation to Reduce Low Birth Weight and Infant and Maternal Morbidity in Rural Nepal
Brief Summary: The purpose of this study was to determine the effects of providing supplements containing alternative combinations of micronutrients during pregnancy on birth weight and other infant and maternal health and nutritional outcomes in a rural area of Nepal.


Options:
A: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: "video doctor," computer module | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: "video doctor," computer module | Intervention Type: BEHAVIORAL; Name: "video doctor," computer module; Assigned to Arm(s): 1, 2
C: Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine/folic acid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine/placebo; Assigned to Arm(s): N/A
D: Arm Label: Folic acid; Type: OTHER; Interventions: Dietary Supplement: Folic acid | Arm Label: Placebo; Type: OTHER; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Folic acid | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
Brief Summary: The purpose of the study is to assess the efficacy and safety of NGX-4010 applied for 60 minutes for the treatment of postherpetic neuralgia (PHN).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 4
B: Intervention Type: DRUG; Name: NGX-4010; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Capsaicin Dermal Patch; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Capsaicin Dermal Patch; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease
Brief Summary: Chlamydial infection is a common, sexually transmitted disease which women can have without knowing. Untreated, it can lead to an infection of the womb and fallopian tubes called pelvic inflammatory disease (PID), which can cause infertility. There has been only one trial of chlamydia screening and this was in American women in 1992 and used outdated tests. We now need to see if screening using modern tests and self-taken swabs works in a high risk, young, multiethnic female population in the United Kingdom (UK).

The study is a randomised trial. It will involve asking women students in college bars to complete confidential questionnaires on sexual health and to provide self-administered vaginal swabs. We have successfully done this in a small pilot study. Participants will be told that the tests are for research purposes only and that if they think they may have been at risk of a sexually transmitted infection they should get checked at a clinic. If the trial shows that chlamydia screening using these new methods prevents PID, extending this community-based intervention nationwide could improve women's reproductive health and wellbeing and might prevent some women from becoming infertile


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tenofovir gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (Universal HEC placebo) | Intervention Type: DRUG; Name: Tenofovir gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo (Universal HEC placebo); Assigned to Arm(s): 2
B: Arm Label: Dapivirine Vaginal Ring; Type: EXPERIMENTAL; Interventions: Combination Product: Dapivirine Vaginal Ring | Arm Label: Placebo Ring; Type: PLACEBO_COMPARATOR; Interventions: Combination Product: Placebo Ring | Intervention Type: COMBINATION_PRODUCT; Name: Dapivirine Vaginal Ring; Assigned to Arm(s): Dapivirine Vaginal Ring | Intervention Type: COMBINATION_PRODUCT; Name: Placebo Ring; Assigned to Arm(s): Placebo Ring
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: BufferGel | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: PRO 2000/5 Gel | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo gel | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: BufferGel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PRO 2000/5 Gel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo gel; Assigned to Arm(s): 3
D: Arm Label: Deferred screening control group; Type: OTHER; Interventions: Procedure: Screening for chlamydia using self-taken vaginal swabs | Intervention Type: PROCEDURE; Name: Screening for chlamydia using self-taken vaginal swabs; Assigned to Arm(s): Deferred screening control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease
Brief Summary: Chlamydial infection is a common, sexually transmitted disease which women can have without knowing. Untreated, it can lead to an infection of the womb and fallopian tubes called pelvic inflammatory disease (PID), which can cause infertility. There has been only one trial of chlamydia screening and this was in American women in 1992 and used outdated tests. We now need to see if screening using modern tests and self-taken swabs works in a high risk, young, multiethnic female population in the United Kingdom (UK).

The study is a randomised trial. It will involve asking women students in college bars to complete confidential questionnaires on sexual health and to provide self-administered vaginal swabs. We have successfully done this in a small pilot study. Participants will be told that the tests are for research purposes only and that if they think they may have been at risk of a sexually transmitted infection they should get checked at a clinic. If the trial shows that chlamydia screening using these new methods prevents PID, extending this community-based intervention nationwide could improve women's reproductive health and wellbeing and might prevent some women from becoming infertile


Options:
A: Arm Label: Cervarix/Engerix-B A Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Biological: Engerix-B | Arm Label: Cervarix/Engerix-B B Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Biological: Engerix-B | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix/Engerix-B A Group, Cervarix/Engerix-B B Group | Intervention Type: BIOLOGICAL; Name: Engerix-B; Assigned to Arm(s): Cervarix/Engerix-B A Group, Cervarix/Engerix-B B Group, Engerix-B Group
B: Intervention Type: PROCEDURE; Name: Home sampling (urine test) for uro-genital C.trachomatis.; Assigned to Arm(s): N/A
C: Arm Label: Deferred screening control group; Type: OTHER; Interventions: Procedure: Screening for chlamydia using self-taken vaginal swabs | Intervention Type: PROCEDURE; Name: Screening for chlamydia using self-taken vaginal swabs; Assigned to Arm(s): Deferred screening control group
D: Arm Label: 1 Screening; Type: EXPERIMENTAL; Interventions: Behavioral: Screening for urogenital Chlamydia trachomatis | Arm Label: 2 Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Screening for urogenital Chlamydia trachomatis; Assigned to Arm(s): 1 Screening

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: KULeuven Intensive Insulin Therapy Study in Medical Intensive Care Patients
Brief Summary: In a previous study, we showed that tight blood glucose control with insulin during intensive care reduced morbidity and mortality of surgical intensive care patients. Whether this intervention also improves prognosis of medical intensive care patients remains unknown. The current prospective, randomized, controlled study will assess the impact of intensive insulin therapy on the outcome of patients in a medical intensive care unit. On admission, patients will be randomly assigned to either strict normalization of blood glucose (80-110 mg/dl) with intensive insulin therapy or the conventional approach, in which insulin infusion is initiated only when blood glucose exceeds 215 mg/dl, to maintain blood glucose levels between 180 and 200 mg/dl.


Options:
A: Arm Label: Intensive Insulin therapy; Type: EXPERIMENTAL; Interventions: Other: Intensive Insulin Therapy | Arm Label: Conventional Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Insulin therapy | Intervention Type: OTHER; Name: Intensive Insulin Therapy; Assigned to Arm(s): Intensive Insulin therapy | Intervention Type: OTHER; Name: Conventional Insulin therapy; Assigned to Arm(s): Conventional Therapy
B: Intervention Type: DRUG; Name: dual-action insulin analog; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: intensive insulin therapy to maintain normoglycemia; Assigned to Arm(s): N/A
D: Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: KULeuven Intensive Insulin Therapy Study in Medical Intensive Care Patients
Brief Summary: In a previous study, we showed that tight blood glucose control with insulin during intensive care reduced morbidity and mortality of surgical intensive care patients. Whether this intervention also improves prognosis of medical intensive care patients remains unknown. The current prospective, randomized, controlled study will assess the impact of intensive insulin therapy on the outcome of patients in a medical intensive care unit. On admission, patients will be randomly assigned to either strict normalization of blood glucose (80-110 mg/dl) with intensive insulin therapy or the conventional approach, in which insulin infusion is initiated only when blood glucose exceeds 215 mg/dl, to maintain blood glucose levels between 180 and 200 mg/dl.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline | Arm Label: hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): hydrocortisone | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: intensive insulin therapy to maintain normoglycemia; Assigned to Arm(s): N/A
C: Arm Label: Hydrocortisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocortisone | Arm Label: Sterile air filled vial; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sterile air filled vial | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone | Intervention Type: DRUG; Name: Sterile air filled vial; Assigned to Arm(s): Sterile air filled vial
D: Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: KULeuven Intensive Insulin Therapy Study in Medical Intensive Care Patients
Brief Summary: In a previous study, we showed that tight blood glucose control with insulin during intensive care reduced morbidity and mortality of surgical intensive care patients. Whether this intervention also improves prognosis of medical intensive care patients remains unknown. The current prospective, randomized, controlled study will assess the impact of intensive insulin therapy on the outcome of patients in a medical intensive care unit. On admission, patients will be randomly assigned to either strict normalization of blood glucose (80-110 mg/dl) with intensive insulin therapy or the conventional approach, in which insulin infusion is initiated only when blood glucose exceeds 215 mg/dl, to maintain blood glucose levels between 180 and 200 mg/dl.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone, Drug: fludrocortisone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: recombinant human insulin, Drug: hydrocortisone | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: recombinant human insulin, Drug: hydrocortisone, Drug: fludrocortisone | Intervention Type: DRUG; Name: recombinant human insulin; Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: hydrocortisone; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: fludrocortisone; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): 1
B: Arm Label: Prednisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Placebo, Prednisone
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone sodium succinate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: hydrocortisone sodium succinate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: intensive insulin therapy to maintain normoglycemia; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: KULeuven Intensive Insulin Therapy Study in Medical Intensive Care Patients
Brief Summary: In a previous study, we showed that tight blood glucose control with insulin during intensive care reduced morbidity and mortality of surgical intensive care patients. Whether this intervention also improves prognosis of medical intensive care patients remains unknown. The current prospective, randomized, controlled study will assess the impact of intensive insulin therapy on the outcome of patients in a medical intensive care unit. On admission, patients will be randomly assigned to either strict normalization of blood glucose (80-110 mg/dl) with intensive insulin therapy or the conventional approach, in which insulin infusion is initiated only when blood glucose exceeds 215 mg/dl, to maintain blood glucose levels between 180 and 200 mg/dl.


Options:
A: Arm Label: NMES; Type: EXPERIMENTAL; Interventions: Device: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA) | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA); Assigned to Arm(s): NMES | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham
B: Intervention Type: DRUG; Name: intensive insulin therapy to maintain normoglycemia; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Mythylprednisolone; Assigned to Arm(s): N/A
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisatracurium, Drug: Cisatracurium besilate | Intervention Type: DRUG; Name: cisatracurium; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Cisatracurium besilate; Assigned to Arm(s): B

Answer: B